Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+6.17%+13.26%+33.13%-1.04% 75.12B
-13.51%-10.70%+17.04%+172.20% 47.63B
+3.25%+52.70%+52.70%+52.70% 49.48B
-4.77%+5.19%-55.09%-54.66% 42.95B
-0.62%+3.64%+64.19%-21.60% 30.72B
-3.23%+5.40%+58.59%+94.94% 24.93B
+6.29%+1.58%+80.16%-51.19% 22.98B
-0.79%-2.78%-10.77%+152.75% 19.56B
-0.13%+3.10%+69.03%+129.42% 17.19B
Average -0.82%+3.10%+34.33%+52.61% 36.73B
Weighted average by Cap. -0.60%+3.99%+29.63%+42.72%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-